Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2

Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain

University of Chicago · NCT06635889

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2
Target enrollment
116
US sites recruiting
1
Study start
March 26, 2025
Record last updated
October 13, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy.

This is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.

Being studied: Bupivacaine; Normal saline

Conditions: Nephrolithiasis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female, aged ≥ 18 years old.
  • Diagnosis of nephrolithiasis planned for flexible or semi-rigid ureteroscopy in the treatment of stone disease with ureteral stenting.

Exclusion Criteria

  • Foley catheterization
  • History of allergy to bupivacaine
  • Antegrade ureteroscopy
  • Transplant or ectopic kidney
  • Ureteral or bladder reconstruction
  • Pregnancy (which is a contraindication to elective ureteroscopy)
  • Dialysis
  • Surgical complication (significant bleeding, ureteral perforation, significant urothelial damage)
  • Suspicion of untreated urinary tract infection
  • History of pelvic radiation
  • Neurologic disease with a diagnosis of neurogenic bladder dysfunction
  • History of chronic pain (fibromyalgia, interstitial cystitis, opioid abuse)

Recruiting US locations

  • The University of Chicago Medical Center

    Chicago, IL 60637

    Site contact: Luke Reynolds, MD · lukereynolds@bsd.uchicago.edu

Study contacts (from the official record)

  • Luke Reynolds, MD · 7137926105 · lukereynolds@bsd.uchicago.edu
  • Leila Yazdanbakhsh · leila.yazdanbakhsh@bsd.uchicago.edu
All healthy volunteers studies in Illinois →
Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain (NCT06635889) | Bored Studies